Chairman of the Board PTC Therapeutics Inc., SHY Therapeutics and Board Member with Berryville Holdings, LLC
Mr. Michael Schmertzler brings over 30 years of experience in investment banking and private equity along with a proven track record of building, growing and leading several early-stage industrial, biotechnology and technology companies.
Mr. Schmertzler serves as chairman of PTC Therapeutics (a public-traded biotechnology company for which he co-led the first institutional funding round in 1998), as well as chairman of SHY Therapeutics, a privately held early-stage biotechnology company. He was previously a managing director of Morgan Stanley & Co. Inc., president of Morgan Stanley Leveraged Capital Funds, a managing director of Shearson Lehman Brothers Kuhn Loeb, and a managing director and chief financial officer of Lehman Brothers Kuhn Loeb. Mr. Schmertzler is a board director with Berryville Holdings, LLC (a cybersecurity-focused software development company). Mr. Schmertzler recently completed his term as independent director of LCPI, the major subsidiary of the post-bankruptcy Lehman Brothers estate. Additionally, he has previously served as a director of Cytokinetics and Idenix. He has also served as chair of the Investment Committee of Credit Suisse First Boston Equity Partners and director of several of its portfolio companies. Mr. Schmertzler is a Governor and Treasurer of the New York Academy of Science, a Trustee of Phillips Academy Andover, and since 1997, a professor at Yale School of Management, where he lectures on economics and the practice of management.